1. Academic Validation
  2. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression

An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression

  • Cell. 2012 Dec 21;151(7):1474-87. doi: 10.1016/j.cell.2012.11.054.
Mrinal Srivastava 1 Mridula Nambiar Sheetal Sharma Subhas S Karki G Goldsmith Mahesh Hegde Sujeet Kumar Monica Pandey Ram K Singh Pritha Ray Renuka Natarajan Madhura Kelkar Abhijit De Bibha Choudhary Sathees C Raghavan
Affiliations

Affiliation

  • 1 Department of Biochemistry, Indian Institute of Science, Bangalore 560 012, India.
Abstract

DNA Ligase IV is responsible for sealing of double-strand breaks (DSBs) during nonhomologous end-joining (NHEJ). Inhibiting Ligase IV could result in amassing of DSBs, thereby serving as a strategy toward treatment of Cancer. Here, we identify a molecule, SCR7 that inhibits joining of DSBs in cell-free repair system. SCR7 blocks Ligase IV-mediated joining by interfering with its DNA binding but not that of T4 DNA Ligase or Ligase I. SCR7 inhibits NHEJ in a Ligase IV-dependent manner within cells, and activates the intrinsic apoptotic pathway. More importantly, SCR7 impedes tumor progression in mouse models and when coadministered with DSB-inducing therapeutic modalities enhances their sensitivity significantly. This inhibitor to target NHEJ offers a strategy toward the treatment of Cancer and improvement of existing regimens.

Figures
Products
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》